Sign up for Table of Contents Alerts.
Email this page
Print this page
Perspectives
Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class
Daniel A. Haber and Jeffrey Settleman
volume 4 | issue 8
august 2005Pages: 1057-1059
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Small molecule kinase inhibitors of the epidermal growth factor receptor (EGFR) have recently been found to exhibit clinical efficacy in the setting of non-small cell lung cancers that harbor activating EGFR mutations. However, the remissions induced by these drugs (Iressa and Tarceva) are typically short-lived, presumably due to acquired drug resistance. We recently reported findings demonstrating that a distinct class of EGFR inhibitors may overcome some mechanisms of secondary drug resistance in these tumors and may therefore be useful in treating lung cancer patients that initially responded to Iressa or Tarceva and eventually relapsed.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.